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Associate Professor of Medicine
Presentation Outline:
1. Overview of environmental challenges and oxidative
lung damage.
2. Introducing alternative remedies to oxidative lung
disease.
3. Ameliorating side effects of: a) therapeutic and b)
accidental radiation lung exposure in mouse model.
4. Chemoprevention of lung tumorigenesis in a rodent
model of chemical carcinogen exposure (tobacco).
5. Chemoprevention of mesothelioma and lung cancer
in a rodent model of environmental carcinogen
exposure (asbestos).
Environmental Insults 
and Oxidative Lung 
Disease
Oxidative Lung Damage
Airborne Toxins
Asbestos fibers
Blood-borne Toxins Radiation
Oxidative Stress and Tissue Damage
Reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) are generated throughout the human body. 
Enzymatic and nonenzymatic antioxidants detoxify ROS and 
RNS and minimize damage to biomolecules. 
Environmental Insults Create an imbalance between the 
production of ROS/RNS and antioxidant capacity leads to 
"oxidative stress" that contributes to the pathogenesis of a 
number of human diseases by damaging lipids, protein, and DNA. 
In general, environmental insults to the lung cause lung 
diseases associated with inflammatory processes that 
generate increased ROS and RNS.
Lung Diseases Associated with 
Oxygen Radicals
Disease Mechanism
Emphysema Tissue injury by oxidants in cigarette smoke
Tissue injury by inflammatory cell oxidants-
α1 proteinase inhibitor (α1PI) inactivation by 
cigarette smoke and inflammatory cells
Adult respiratory 
distress syndrome
Inflammatory cell release of oxidants- α1PI 
oxidative inactivation by inflammation cells
Hyperoxia
Hyperoxia-mediated oxygen radical synthesis 
in cells
Idiopathic 
pulmonary fibrosis
Inflammatory cell oxidant release 
Glutathione deficiency
Asthma Inflammatory cell release of oxidants
Decrease in superoxide dismutase activity in 
bronchial epithelial cells
Comhair SA, Erzurum SC, Am J Physiol Lung Cell Mol Physiol.  
Pharmacologic Therapy for Treatment of 
Acute Respiratory Distress Syndrome 
Research on pathophysiology & genetics of 
ALI/ARDS continues to advance. 
Critical molecular pathways in disease development 
and specific genetic factors that alter the expression 
of disease are identified. 
Despite these advances, 
pharmacologic therapies have yet to 
be developed for the prevention or 
treatment of disease.
Pharmacologic Therapy for Treatment of 
Acute Respiratory Distress Syndrome 
Hooper M, Bernard G, June 2011.
The Need for New Safe and Effective 
Drugs to Treat Lung Disease
Use of Botanicals And Dietary Supplements 
Derived From Natural Substances
An expanding body of preclinical evidence suggests 
that a number of botanicals have the potential to 
impact a variety of human diseases including oxidative 
lung disease.
Therefore, non-toxic natural agents could be useful 
either alone or in combination with conventional 
therapeutics for the prevention or therapy of 
oxidative lung disease.
Nutrition As Therapy And Not Simply 
“Supportive Care”
JAMA, Oct 2011
Annual sale of Medicinal Herbs in the US  is > 3 Billion $$$
More than 60 million consumers in the U.S. take herbal
remedies. More physicians are recommending herbal
medicines and some health insurance plans offer coverage
for alternative health treatments such as herbal remedies.
In 1993 the NIH opened the National Center for 
Complementary and Alternative Medicine (NCCAM) 
which along with the Office of Dietary Supplements 
(ODS) aim to promote the safety, effectiveness, and 
biological action of botanical products.
Usefulness of Dietary Supplements
Drug Development From Bioactive 
Dietary Agents
Dietary Antioxidants
(Vegetables and Fruits)
Purification
Of Main Active 
Components
Evaluation 
in Cell Culture 
and Animal 
Models
Elucidation
of Mechanism
of Action
Determining
Bioavailability/ 
Biospecificity
Testing in
Clinical Trials
DRUG 
DEVELOPMENT
Botanicals with antioxidant properties currently 
being evaluated in lung disease and cancer
Green Tea Turmeric Flaxseed
TomatoesGrapes Pomegranate Broccoli
Epigallocatechin-3-gallate (EGCG) Curcumin
Secoisolariciresinol
Diglucoside (SDG)
Dietary Agents
Dietary Agents
Chemical 
Structures
Resveratrol Lycopene Delphinidin
Chemical 
Structures
Sulforaphane
Flaxseed:
“an ancient remedy 
in a modern world”
The father of modern medicine, 
Hippocrates, the Greek physician, by 650 
B.C. wrote about the use of flax to relieve 
inflammation of mucous membrane and for 
the relief of abdominal pains and diarrhea. 
By the 8th Century A.D. Charlemagne one 
the greatest medieval kings, considered flax 
so important that for the health of his 
subjects he passed laws and regulation 
requiring its consumption. 
Mahatma Ghandi said that when flaxseed 
was added to people's diet their health 
improved.
FLAXSEED
Intestinal 
Bacteria
Plant Lignan 
Precursors
•Secoisolarisiresinol 
diglycoside
(SDG)
•matairesinol
Lignans
•Enterodiol (ED)
•Enterolactone (EL)
Biological Properties
***Antioxidative
Antiproliferative
Antiangiogenic
Estrogenic/Antiestrogenic
Cancer Protection
DHA
(Docosahexanoic Acid)
α-Linolenic Acid
EPA
(eicosapentanoic Acid)
**Anti-inflammatory
Omega-3 Fatty Acids
Flaxseed Lignan Structure
Resveratrol
Curcumin
Quercetin
Secoisolariciresinol 
diglucoside (SDG)
A bi-phenolic with potent 
antioxidant properties
We Identified Flaxseed  and its main Lignan (SDG) As A Potent 
Inhibitors Of Oxidative Lung Injury In Diverse Animal Models
Protective Properties of Flaxseed in Preclinical 
Models of Cancer &  Acute/Chronic Lung Damage
Flaxseed
and SDG 
Lignan RADIATIONPNEUMONOPATHY (acute/chronic)
ASBESTOS-INDUCED MALIGNANT 
MESOTHELIOMA
TOBACCO CARCINOGEN-
INDUCED LUNG CANCER
ACID ASPIRATION-INDUCED
LUNG INJURY
HYPEROXIC LUNG INJURY
ISCHEMIA-REPERFUSION
LUNG INJURY
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Free Radical Scavenging by Flaxseed Lignan SDG in 
γ-irradiated lung Endothelial cells
Lee et.al, 2009
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Genetic profiling of flaxseed in lung
(30,000 gene array of entire mouse genome)
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Principle Component Analysis
6.8% of all mouse genes in lung tissues are significantly modified by flaxseed
Dukes et.al, 2012
Lung Gene Expression Profiling of Genes With >1.5x fold Change in 
Individual Flax-fed Mice as Compared to Mean of Control
Red indicates up-regulation, green down-regulation
Dukes et.al, 2012
Flaxseed induces in lung dose-dependent 
expression of antioxidant enzymes
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NQO-1
β-actin
1 2 643 5
HO-1
10% FS5% FS
B C NQO-1HO-1
32 kD
31 kD
*
0% FSHeme oxygenase-1 (HO-1)
confers protection against 
a variety of oxidant-
induced cell and tissue 
injury. 
Nicotinamide quinone 
oxidoreductase 1 
(NQO1) protects against 
toxicity of electrophiles 
and reactive oxygen 
intermediates 
Lee et.al: Am J Physiol Lung Cell Mol Physiol. 2008;294(2):L255-65
ARE Phase II EnzymesCell Survival genes
Nrf2
Keap-119S
20S
19S
PKC
Flaxseed 
Lignans
?
Increased Antioxidant Enzyme Expression in Lungs
Nrf2
Degradation
PERK
PI3K
MAPK
Flaxseed 
Lignans
?
Nucleus
P
Maf
Transcription 
(H0-1, NQO1, GST)
Given the direct free radical scavenging
properties of the flaxseed lignans and the 
robust boost of antioxidant tissue defenses, 
We Hypothesized, That Dietary Flaxseed 
and Will Ameliorate Oxidative Acute 
and Chronic Lung Damage such as that 
resulting from Radiation Exposure, 
Modeled In Mice
HYPOTHESIS
DIRECT OXIDANT
STRESS
•Radiation
INDIRECT OXIDANT 
STRESS
•Neutrophils
•Macrophages
•Endothelial Cells
DNA damage
Cytokine release
Tissue oxidation
Apoptosis Inflammatory Cells 
OXIDATIVE 
LUNG INJURY
Lung leakiness / Edema
Chemokine Release
ROS
Flaxseed/
FS Lignans
Flaxseed/
FS Lignans
RADIATION 
PNEUMONOPATHY
Radiation Pneumonopathy Resulting 
from Radiotherapy
Radiation Therapy is commonly used to treat lung 
cancer and other thoracic malignancies 
(mesothelioma, breast cancer, esophageal cancer, 
lymphomas). 
Up to 30% of patients irradiated for lung cancer and 
10-15% of other thoracic oncology patients develop 
clinically significant radiation lung injury.
Radiation Damage to the Lung is characterized by:
A) Pneumonia-like symptoms (Inflammation)
B) Fibrotic lung damage (irreversible).
Radiation Toxicity to Normal Tissues
The usefulness of thoracic radiotherapy in the 
treatment of cancer is greatly limited by toxicity 
of ionizing radiation (radiation 
pneumonopathy).
Therefore, if we protect “normal” lung 
parenchyma from radiation injury, we 
will increase  the ability to deliver 
tumoricidal radiotherapy doses. 
International Journal of Radiation Oncology, Biology, Physics 55(1): 110–115, 2005
Incidence of Radiation Pneumonitis is Exacerbated when 
Concurrent Chemoradiation is Administered
Incidence of Grade 2 
radiation pneumonitis as a 
function of the relative lung 
volume irradiated to more 
than 20 Gy (V20) of patients 
treated with radiotherapy 
alone (open circles) or with 
chemo-radiotherapy (closed 
circles) . 
Patients receiving chemotherapy had a sharper increase in risk of radiation 
pneumonitis as the volume of normal lung exposed to 20 Gy increased.
SARRP: Small Animal Radiation 
Research Platform
• A powerful research platform based on
state-of-the-art Image Guided Micro-
Irradiation techniques
• The SARRP research platform
incorporates CT imaging with precise
radiation delivery to enable pinpointing
of an exact anatomical target to
confidently deliver 0.5 mm beams to
that point.
• The SARRP platform can then deliver
single or multiple beams of radiation to
the target with the upmost accuracy,
matching the clinical techniques used
in oncology departments around the
world
A B
DC
Irradiation of Mouse Thorax Using the Small
Animal Radiation Research Platform (SARRP)
Use of the SARRP, to
deliver a single
fraction 13.5 Gy X-
ray irradiation to the
thorax.
Shielding is provided
for the head only as
the highly collimated
field edge already
limits dose to the
abdomen/pelvis.
Mouse Radiographs
Cephalic
margin
Caudal
margin
XRT
(XRT=X-Ray Treatment)
Flaxseed Improves Mouse Survival 4 
Months Post Thoracic Irradiation
35% vs. 65% Survival for Control and Flaxseed-
supplemented diets, respectively
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Dietary Flaxseed Ameliorates Radiation-
Induced Pneumonitis (Inflammation) in Mice
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Alveolar Neutrophils Alveolar Macrophages
Lee et.al, 2009
Antifibrotic Role of Flaxseed
Cancer Biology and Therapy, 2009
Flaxseed 
Decreased 
Radiation-
Induced 
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Deposition in 
Lungs
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Dietary Flaxseed given Preventively:
 Improves Survival
 Prevents Radiation-induced
•Oxidative Tissue Injury
•Pneumonitis
•Inflammation
• Lung Fibrosis
•Cytokine Secretion
•Does NOT protect Tumor
Summary
Lung-Related Symptoms Linked to Incidents of 
Accidental Exposure to Radiation
Respirology (2012) 17, 66–71


Mitigation of Radiation Pneumonopathy 
by Wholegrain Flaxseed
T=-3
Wks
Radiation
(XRT)
T=0 T=+2
Wks
T=+4
Wks
T=+6
Wks T= 4 months
(sacrifice)Time of FS Diet Initiation
EXPERIMENTAL MODEL
GOAL: Determine whether Flaxseed (FS) attenuates lung toxicity and lethality related 
to thoracic radiation (external exposure to ionizing radiation)
Separate mouse cohorts for each time-point
Christofidou-Solomidou, BMC Cancer, 2011
Mitigation of Radiation Damage by Flaxseed
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BAL PROTEINS 
(LUNG DAMAGE)
OXIDATIVE LUNG DAMAGE
Administering flaxseed 
2,4,6 weeks POST 
radiation exposure is 
still protective from 
radiation damage
Christofidou-Solomidou, BMC Cancer, 2011
Improvement of Animal Survival by Flaxseed 
Given Post Radiation Exposure
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Mitigation of Radiation Damage by 
Dietary Flaxseed
Christofidou-Solomidou, BMC Cancer, 2011

Presentation Outline:
1. Overview of environmental challenges and oxidative
lung damage.
2. Introducing alternative remedies to oxidative lung
disease.
3. Ameliorating side effects of: a) therapeutic and b)
accidental radiation lung exposure in mouse model.
4. Chemoprevention of lung tumorigenesis in a rodent
model of chemical carcinogen exposure (tobacco).
5. Chemoprevention of mesothelioma and lung cancer
in a rodent model of environmental carcinogen
exposure (asbestos).
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Lung Cancer
• Leading cause of 
cancer deaths in 
the US (>160,000 
per year). 
Clinics In Chest Medicine 2011; 32:605-644 
(DOI:10.1016/j.ccm.2011.09.001 )-Copyright © 2011 Elsevier Inc.
• Probably >90% 
due to tobacco 
smoke exposure.
Lung Cancer
• Surgery offers the sole prospect for cure-a small 
percentage of lung cancer patients are candidates.
• Focus on novel PREVENTIVE strategies 
whereby known industrial, environmental or 
tobacco-derived carcinogens can be prevented 
from causing tissue damage leading to cancer 
development. 
• Dietary modulation and Chemoprevention may 
be considered for control of the lung cancer 
epidemic. 
Rodent Models Of Chemical 
Carcinogenesis-lung Cancer
Rodent models of lung cancer that develop 
after exposure to a chemical carcinogen are 
valuable to study mechanisms of 
carcinogenesis and pathogenesis, for early 
detection, and to test chemopreventive 
and therapeutic agents.
Tobacco Smoke Exposure (Rodents)
Daily Exposure to Tobacco Smoke for 6 hrs
Sacrifice Mice
Evaluate tumor burden
5
Mo
Months 1-5
9
Mo
4 Months Recovery)
Microprocessor-
controlled cigarette 
smoking machineCollecting and mixing chamber for 
rodent exposure studies
1. Benzo-alpha pyrene (B[α]P)
2. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
3. Dimethylbenz(a)anthracene (DMBA)  
4. Urethane 
Alternative: Purified TobaccoCarcinogen(s)
•The polycyclic aromatic hydrocarbon (PAH) Benzo[a]pyrene (B[a]P) is one of the 
most prevalent environmental carcinogens-(Combustion of coal, oil, gas, wood, 
garbage, tobacco, and charbroiled meat).
Weekly
i.p injections of
B[a]P (1 mg/mouse)
Sacrifice Mice
Evaluate tumor burden
5
Mo
Weeks 1-4
6
Mo
8
Mo
Rodent Model of Benzo[a]Pyrene-
Induced Chemical Carcinogenesis
Use of an inbred mouse strain 
(A/J) with increased sensitivity to 
chemical carcinogen-induced 
lung carcinogenesis
Histological Detection of Lung Tumor 
Nodules in Mice Exposed to B[α]P
5 Months4 Months 8 Months6 Months
BENZO[a]PYRENE-CHEMICAL 
CARCINOGENESIS MODEL
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Tobacco smoke exposure
Generation of DNA 
reactive products
DNA Adducts,
Chromosomal Effects
Mutations
LUNG 
CANCER
PAH, NNK, other carcinogens
(example: Benzo[a]pyrene)
ROS, peroxynitrite, lipid peroxidation, 
8-hydroxy-deoxyguanosine
Methyl Adducts, pyridyloxybutyl
Adducts, SCE, Micronuclei, 
chromosome instability
P53, K-Ras, others
Flaxseed 
Lignans
Adapted from Hecht, 1999
ASBESTOS
EXPOSURE
Asbestos Exposure and Malignant Mesothelioma
Asbestos fiber inhalation can lead to malignant
mesothelioma, lung cancer, as well as pulmonary fibrosis.
MM is a highly aggressive cancer that arises from the
mesothelial cells of the pleura and peritoneum with a median
survival of about 1 year.
Current therapies, other than surgery in very early disease,
are not curative.
Presently, MM causes about 3,000 deaths per year in the US 
and an additional 5,000 deaths/year in Western Europe.


1. Can we remediate asbestos without moving it from the
original disposal site?
2. What do we know about the fate and transport of
asbestos in the environment by water and air?
3. What do we know about the exposure pathways that were
responsible for the mesothelioma cluster in Ambler? And
why is the incidence higher in women?
4. Is susceptibility to mesothelioma genetic?
5.Can asbestos-related disease be prevented?
6. Is there a blood test to determine whether a person will
get asbestos-related disease?
Asbestos fate, exposure, remediation, 
and adverse health effects” 
Evaluation of Flaxseed and its 
Lignan SDG in Asbestos-
Exposed Cells
AND 
Rodent Models of Accelerated 
Malignant Mesothelioma
Modeling Asbestos Exposure to Study of 
Mechanism of Inflammatory Cell Activation
Inhaled asbestos fibers work their way into the lung and ultimately to the pleural 
surface. They are taken up by tissue phagocytes, primarily macrophages. This 
stimulates intracellular ROS and activates NF-kb and the inflammasome inducing 
the release of numerous cytokines and mutagenic ROS
Using human and mouse macrophages and mesothelial cells, we will 
evaluate the ability of the anti-oxidant Secoisolariciresinol diglucoside 
(SDG) to interfere with asbestos-induced ROS generation, cytokine 
secretion and inflammasome activation in vitro.
Evaluation of the Lignan SDG in Blocking Asbestos-
Induced Macrophage Activation
Asbestos 
Exposure
24h
(+3h, +4h, +6h, +8h)
TNF-α
IL1-β
ROS
ROS
ROS
ROS
ROS
ROS
ROS ROS
0h
SDG±
Post-asbestos
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Using at least 2 models of mice genetically predisposed to develop 
mesothelioma after asbestos exposure, we will: Evaluate the ACUTE effects of 
Flaxseed and SDG on a single dose of asbestos in mice; test whether Flaxseed 
and SDG inhibits CHRONIC effects such as the development of tumors and 
lung fibrosis  in genetic models of accelerated, asbestos induced MM.
Testing SDG in Asbestos-Induced Mesothelioma
Data from this work will provide important evidence for 
the usefulness of this bioactive natural product in 
blunting cancer development from asbestos exposure 
and provide insight in the mechanisms involved.
Chemoprevention of Asbestos-Induced Malignant 
Mesothelioma Using Dietary Flaxseed
If our studies show efficacy with safety, our 
long-term goal would be the evaluation of 
Flaxseed and SDG as chemopreventive agents 
for mesothelioma in exposed populations.
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